Predicting the costs of managing patients with chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 99, Issue 10, 2005, Pages 1325-1333

  Mapel, Douglas W ^a   McMillan, Garnett P ^b   Frost, Floyd J ^c   Hurley, Judith S ^c   Picchi, Maria A ^c   Lydick, Eva ^a   Spencer, Michael D ^d  

^a LOVELACE CLINIC FOUNDATION   (United States)

^b Behavioral Health Research Center of the Southwest   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Costs; Healthcare resource utilisation

Indexed keywords

OXYGEN;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOME CARE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT CARE; OXYGEN THERAPY; PHARMACEUTICAL CARE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SYMPTOMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; NEW MEXICO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 24344451232     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.03.001     Document Type: Article

References (37)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Workshop Report (Updated 2003). Accessed at www.goldcopd.com, March 25th, 2004
2. Minino AM, Smith BL. Preliminary data for 2000. National Center for Health Statistics. National Vital Statistics Reports, No. 49(12). Hyattsville, MD, 2001. Preliminary data for 2000. National Center for Health Statistics. National Vital Statistics Reports, No. 49(12). Hyattsville, MD, 2001.
3. Murray CJ, Lopez AD, Mathers CD, Stein C. The global burden of disease 2000 project: Aims, methods and data sources. Global Programme on Evidence for Health Policy Discussion Paper No. 36. World Health Organisation, November 2001 (revised).
4. C.J. Murray A.D. Lopez The Global Burden of Disease: A comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020 1996 Harvard University Press Cambridge
5. C.J. Murray A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study Lancet 249 1997 1498-1504
6. S.D. Sullivan S.D. Ramsey T.A. Lee The economic burden of COPD Chest 117 Suppl. 2 2000 5S-9S
7. M. Friedman D.E. Hilleman Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options Pharmacoeconomics 19 2001 245-254
8. M.A. Faulkner D.E. Hilleman The economic impact of chronic obstructive pulmonary disease Expert Opin Pharmacother 3 2002 219-228
9. L. Jacobson P. Hertzman C.G. Lofdahl B.E. Skoogh B. Lindgren The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991 Respir Med 94 2000 247-255
10. F. Andersson S. Borg S.A. Jannson et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 96 2002 700-708
11. D.E. Hilleman N. Dewan M. Malesker M. Friedman Pharmacoeconomic evaluation of COPD Chest 118 2000 1278-1285
12. M.S. Niederman J.S. McCombs A.N. Unger A. Kumar R. Popovian Treatment cost of acute exacerbations of chronic bronchitits Clin Ther 21 1999 576-591
13. P. Calverley R. Pauwels J. Vestbo et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial Lancet 361 2003 449-456
14. P.S. Burge P.M.A. Calverley P.W. Jones S. Spencer J.A. Anderson T.K. Maslen Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial BMJ 320 2000 1297-1303
15. W. Vincken J.A. van Noord A.P. Greefhorst et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium Eur Respir J 19 2002 209-216
16. M. Levine R. Taylor M. Ryan M. Sculpher Decision-making by healthcare payers Respir Med 96 Suppl. C 2002 S31-S38
17. A.M.K. Huib The GOLD classification has not advanced understanding of COPD Am Rev Respir Crit Care Med 170 2004 212-213
18. D.D. Sin J.V. Tu Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 580-584
19. D.W. Mapel J.S. Hurley F.J. Frost H.V. Peterson M.A. Picchi D.B. Coultas Health care utilization in chronic obstructive pulmonary disease: A case-control study in a health maintenance organization Arch Intern Med 160 2000 2653-2658
20. D.W. Mapel M. Pearson Obtaining evidence for use by healthcare payers on the success of chronic obstructive pulmonary disease management Respir Med 96 Suppl. C 2002 S23-S30
21. M.E. Charlson P. Pompei K.L. Ales C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chron Dis 40 1987 373-383
22. R.A. Deyo D.C. Cherkin M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613-619
23. P. Diehr D. Yanez A. Ash M. Hornbrook D.Y. Lin Methods for analyzing health care utilization and costs Ann Rev Public Health 20 1999 125-144
24. S. Macran P. Kind M. Spencer Predicting quality of life in chronic obstructive pulmonary disease Eur Respir J 20 Suppl. 38 2002 156s
25. D.B. Coultas D. Mapel R. Gagnon E. Lydick The health impact of undiagnosed airflow obstruction in a national sample of United States adults Am J Respir Crit Care Med 164 2001 372-377
26. M.T. Halpern R.H. Stanford R. Borker The burden of COPD in the USA: results from the confronting COPD survey Respir J 97 Suppl. C 2002 S81-S89
27. M.D. Spencer Economic implications of reductions in COPD re-hospitalisation due to treatment with inhaled corticosteroids Thorax 579 Suppl. 3 iii 59 2002 P41
28. A.F. Connors N.V. Dawson C. Thomas et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease Am J Respir Crit Care Med 154 1996 959-967
29. T.A. Seemungal G.C. Donaldson A. Bhowmik D.J. Jeffries J.A. Wedzicha Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 1608-1613
30. M. Miravitlles C. Murio T. Guerrero R. Gisbert Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD Chest 121 2002 1449-1455
31. D.D. Sin J.V. Tu Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 580-584
32. J.B. Soriano J. Vestbo N.B. Pride V. Kiri C. Maden W.C. Maier Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Eur Resp J 20 2002 1-7
33. J.B. Soriano V.A. Kiri N.B. Pride J. Vestbo Inhaled corticosteroids with/ without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients Am J Respir Med 2 2003 67-74
34. M.J. Price C. Hurrell J. Efthimiou H.V. Medley Health care costs of treating exacerbations of chronic obstructive pulmonary disease Eur Respir J 14 1999 30s
35. D.M. Mannino A.S. Buist T.L. Petty P.L. Enright S.C. Redd Lung function and mortality in the United States: Data from the first National Health and Nutrition Examination Survey follow up study Thorax 58 2003 388-393
36. N.R. Anthonisen J.E. Connett P.L. Enright J. Manfreda Hospitalizations and mortality in the lung health study Am J Respir Crit Care Med 166 2002 333-339
37. E.F.M. Wouters Economic analysis of the Confronting COPD survey: overview of results Respir J 97 Suppl. C 2002 S3-S14